Vir Biotechnology, Inc. (Nasdaq: VIR) today provided key program updates, including new positive data from the ongoing SOLSTICE Phase 2 trial in chronic hepatitis delta (CHD). Participants receiving ...

Learn how spectroscopy facilitates non-invasive, real-time bio-monitoring, enhancing decision-making in healthcare, ...

Insmed's CEO said months ago that the commercial opportunity for the biotech's newly approved lung disease drug was "huge." ...

Investors poured into a room at #JPM26 to see how Revolution Medicines' CEO would dance around questions they knew he ...

Using a technique called ancestral sequence reconstruction (ASR), researchers at Wageningen University & Research in the ...

Ai Technology Group Inc. (OTCID:AIPG) (the “Company”) and AVM Biotechnology Inc. (“AVM”, the Washington State company that is the subject of the proposed merger) provide this joint press release. The ...

Nvidia and U.S. pharma giant Eli Lilly will spend $1 billion building a new joint research lab in the San Francisco Bay area ...

A team of researchers led by bioengineer Shaochen Chen will use 3D printing techniques to shape stem cells produced by local firm Allele Biotechnology ...

Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the ...

He found that Brassicaceae vegetables are linked to lower cancer risk due to powerful phytochemicals like sulforaphane.

Shares of the biotech company surged 1,681% in 2025, making it the best performer in the Stoxx Europe 600 by a wide margin.

This floor price is at a premium to the stock's recent performance. On Monday, shares of Biocon settled 2 per cent lower at ...